- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Inhibikase Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
| 14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
| 14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
| 14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
| 14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 436 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 201 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 221 | GlobeNewswire (Europe) | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
| 21.10.24 | Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | 248 | GlobeNewswire (Europe) | -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 170,40 | +0,12 % | Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% | ||
| TEVA | 14,150 | +0,35 % | Das große Dossier von ratiopharm: So gesund lebt die Generation 50plus / Neue Bevölkerungsumfrage + Interview mit Trendforscherin | Ulm (ots) - Wie sehr rückt die eigene Gesundheit in den Fokus, wenn man die Lebensmitte überschritten hat? Was motiviert zu einem gesünderen Lebensstil - und was steht dem manchmal im Weg? Mit dem großen... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,772 | -0,14 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments | - Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized - - LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,250 | +0,81 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 23,200 | -7,20 % | Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 ... | TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce its financial and operational... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 5,400 | 0,00 % | Astria Therapeutics licenses navenibart rights to Kaken for HAE | ||
| AMARIN | 12,600 | -1,56 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 19,700 | -0,51 % | Nektar Therapeutics Reports Second Quarter 2025 Financial Results | SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025.
Cash... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,50 | -0,21 % | Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma | Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adultsAccelerated approval based on an overall response... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,438 | +5,58 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,650 | -3,27 % | XORTX Therapeutics Inc (3): XORTX Therapeutics closes $114,500 (U.S.) financing | ||
| MADRIGAL PHARMACEUTICALS | 294,30 | -0,94 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates | Second-quarter 2025 Rezdiffra (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 40,150 | +0,32 % | Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics | Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate... ► Artikel lesen | |
| OPUS GENETICS | 0,893 | -1,87 % | Opus Genetics, Inc.: Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 90,20 | -0,22 % | Verona Pharma ADR: EPS übertrifft Schätzungen um 0,11 $ - Umsatz besser als erwartet |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -9,24 % bei einem Aktienkurs von 1,425 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.